Financial Performance - The company reported a basic earnings per share of -0.7900 yuan for 2024, a decrease of 429.17% compared to 0.2400 yuan in 2023 [1] - The net profit for 2024 was -0.63 billion yuan, representing a decline of 431.58% from 0.19 billion yuan in 2023 [1] - The operating revenue decreased by 27.84% to 2.41 billion yuan in 2024 from 3.34 billion yuan in 2023 [1] - The return on equity was -8.71% in 2024, a significant drop from 2.47% in 2023 [1] Shareholder Structure - The top ten unrestricted shareholders hold a total of 56.7154 million shares, accounting for 70.9% of the circulating shares, with a decrease of 404,800 shares compared to the previous period [2] - The largest shareholder, Tibet Jiakang Times Technology Development Co., Ltd., holds 46.678 million shares, representing 58.35% of the total share capital, with no change [3] - New entrants among the top shareholders include He Jie, Pan Jie, and others, while several previous shareholders have exited the top ten list [3][4] Dividend Policy - The company has announced no distribution or capital increase for the current period [5]
多瑞医药:2024年报净利润-0.63亿 同比下降431.58%